Common prostate drugs linked to cancer death risk in major study

A new analysis published in JAMA Oncology reveals that 5-alpha reductase inhibitors—widely prescribed to treat enlarged prostates—may increase prostate cancer mortality in some patients. The finding could reshape treatment guidelines and raise questions for the millions of men taking these medications worldwide.

Originaltitel: Association of 5a-reductase inhibitors with prostate cancer mortality (May 19, 2022, 10.1001/jamadermatol.2022.1501)